Clinical Trial Update: Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) [Phase 3]

View source ↗

Summary

The PROMINENT phase 3 trial evaluating pemafibrate in adults with type 2 diabetes and dyslipidemia was terminated and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Type 2 Diabetes Mellitus

Drugs mentioned

• Pemafibrate (pemafibrate)

Snippet

Sponsor: Kowa Research Institute, Inc. | Conditions: Type2 Diabetes, Dyslipidemia | Phase 3 | Status: TERMINATED | Results posted: 2025-09-25